Our top officers have extensive experience with startup and middle-market companies, specifically in the fields of medical devices, technology development, and biomedical science. In addition to our team members below, learn more about our scientific advisory board.
Physician and entrepreneur with 30+ years of clinical experience, Dr. Isaac Eliaz is a Gal-3 expert and inventor of the Gal-3 inhibitor. He founded Amitabha Apheresis Clinic and ecoNugenics (acquired in 2023 by a leading private equity firm). A multi-patent holder and author, Dr. Eliaz has led research in integrative medicine, developing therapies for sepsis and cancer.
Accomplished, senior accounting and financial management executive with more than 20 years of experience in the medical device, life science, and semiconductor industries. Prior to finance, worked in product development as a chemical engineer.
Business development, strategy, and operations veteran, Anat Stern has 18 years of experience in healthcare and biotechnology. She managed ecoNugenics, a nutraceutical company specializing in Galectin-3, for 7 years, leading to its successful private equity acquisition in 2023. Anat now leads ETI’s key strategic and operational efforts.
With an MBA and 20+ years of experience in financial management, business development, and M&A, Bryan has scaled ventures across healthcare and medtech. He specializes in securing capital, go-to-market strategies, and fostering relationships for growth.
Expert in acute kidney failure and chronic kidney disease with more than 30 years of clinical experience. Dr. Chertow has conducted sponsored and NIH-funded trials throughout his career and maintained a research program devoted to improving kidney patient treatment.
Dr. Cumming is a biotechnology expert with over 25 years of experience, including senior roles at Genetics Institute and GlycoDesign Inc., where he advanced therapeutics targeting cancer, inflammation, and infectious diseases. He co-founded Translational Medicines, Inc., and served as CSO for the International Consortium.
Dr. Alpert brings decades of regulatory expertise, including 13 years at the FDA, where she served as Director of the Office of Device Evaluation (1993-1999). She will guide ETI through FDA pathways, optimizing submissions and securing key regulatory approvals for XGal-3®.
Ilana brings over 30 years of experience in QA & RA , including 11 years as an investigator for the United States FDA. She has held roles such as Regulatory Compliance Manager at Teva Pharmaceuticals, Director of Compliance at Omrix (a J&J subsidiary), and Director of Quality at Orgenics (an Alere subsidiary).
Eliaz Therapeutics is seeking seasoned managers who are experts in the medical field, marketing strategy, and regulatory landscape.
